Skip to main content
. 2013 Nov 19;1(1):2–14. doi: 10.1002/acn3.19

Figure 5.

Figure 5

Therapeutic window. (A) Vehicle or KD025 was administered (arrows) starting 1, 3 or 6 h after fMCAO and continued until sacrifice at 48 h (four doses). (B) Infarct volumes (indirect method) are shown after postischemic vehicle or KD025 (200 mg/kg) treatment starting 1, 3 or 6 h after dMCAO. KD025 was efficacious when administered 1 or 3 h but not 6 h after stroke onset (n = 8, 14, 7 vehicle, and 8, 15, 7 KD025, at 1 h, 3 h and 6 h time points, respectively). *P < 0.05 versus vehicle. Boxes, median, and interquartile range; whiskers, min–max; +, mean. Two-way ANOVA followed by Sidak’s multiple comparisons test.